CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Coherus Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.96−0.03 (-3.16%)
Close on Oct 19, 2026
- Market cap
- $148.42M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
45.5%
70M of 155M shares
Institutional holders
147
11 new, 20 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 8,934,952 | 5.80% | 13G (passive) | Jun 30, 2026 |
| Evgeny Zaytsev ("Zaytsev") | 7,602,708 | 6.50% | 13G (passive) | Sep 5, 2025 |
| Timothy G. Youngquist 2020 Irrevocable Trust | 12,750,800 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CHRS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 13,050,623 | 8.45% | $18.27M | +759,823 | 3.58% |
| BlackRock, Inc. | 12,003,316 | 7.77% | $16.80M | +1,638,242 | 0.00% |
| Vanguard Capital Management LLC | 5,949,490 | 3.85% | $8.33M | +496,728 | 0.00% |
| Geode Capital Management, LLC | 3,685,567 | 2.39% | $5.16M | +563,989 | 0.00% |
| Samsara BioCapital, LLC | 3,428,571 | 2.22% | $4.80M | – | 0.39% |
| Kohlberg Kravis Roberts & Co. L.P. | 3,036,076 | 1.97% | $4.18M | – | 0.07% |
| State Street Corp | 2,382,305 | 1.54% | $3.34M | +56,446 | 0.00% |
| Two Sigma Investments, LP | 2,259,412 | 1.46% | $3.16M | −42,589 | 0.00% |
| CM Management, LLC | 2,100,000 | 1.36% | $2.94M | – | 1.96% |
| C WorldWide Group Holding A/S | 1,928,464 | 1.25% | $2.70K | – | 0.07% |
| Alyeska Investment Group, L.P. | 1,733,234 | 1.12% | $2.43M | −516,766 | 0.01% |
| Hudson Bay Capital Management LP | 1,693,000 | 1.10% | $2.37M | −11,980 | 0.01% |
| Aqr Capital Management LLC | 1,330,201 | 0.86% | $1.86M | +124,155 | 0.00% |
| Charles Schwab Investment Management Inc | 1,228,069 | 0.79% | $1.72M | +72,168 | 0.00% |
| Panagora Asset Management Inc | 1,137,325 | 0.74% | $1.59M | −321,985 | 0.00% |
| Northern Trust Corp | 1,129,470 | 0.73% | $1.58M | +215,670 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,015,991 | 0.66% | $1.42M | +66,072 | 0.00% |
| Nomura Asset Management International Inc. | 899,999 | 0.58% | $1.26M | – | 0.00% |
| Vanguard Portfolio Management LLC | 883,454 | 0.57% | $1.24M | +278,929 | 0.00% |
| UBS Group AG | 760,358 | 0.49% | $1.06M | +213,149 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 147 | 70M | 45.5% | 11 / 62 | 42 / 20 | 6M | 7M |
| Q1 2026 | 158 | 72M | 46.3% | 42 / 47 | 37 / 10 | 28M | 4M |
| Q4 2025 | 128 | 57M | 37.1% | 26 / 39 | 33 / 8 | 11M | 5M |
| Q3 2025 | 114 | 52M | 33.5% | 21 / 37 | 30 / 17 | 2M | 6M |
| Q2 2025 | 112 | 56M | 36.0% | 15 / 33 | 33 / 20 | 3M | 9M |
| Q1 2025 | 117 | 62M | 40.1% | 13 / 41 | 31 / 18 | 6M | 10M |
| Q4 2024 | 124 | 66M | 42.5% | 31 / 30 | 34 / 35 | 10M | 22M |
| Q3 2024 | 128 | 77M | 50.1% | 17 / 41 | 32 / 22 | 19M | 13M |
| Q2 2024 | 135 | 83M | 53.7% | 24 / 47 | 36 / 24 | 8M | 14M |
| Q1 2024 | 137 | 88M | 57.2% | 23 / 39 | 55 / 42 | 22M | 18M |
| Q4 2023 | 156 | 85M | 54.9% | 32 / 48 | 54 / 42 | 18M | 26M |
| Q3 2023 | 169 | 94M | 60.9% | 42 / 64 | 47 / 33 | 23M | 15M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CHRS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,953,617 | 2.56% | $5.54M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,217,678 | 2.08% | $4.50M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,863,589 | 1.21% | $2.61M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,422,262 | 0.92% | $2.01M | 0.01% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 927,830 | 0.60% | $1.48M | 0.03% | May 29, 2026 |
| Nomura Healthcare Fund | 900,000 | 0.58% | $1.26M | 0.17% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 783,155 | 0.51% | $1.25M | 0.00% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 741,539 | 0.48% | $1.04M | 0.01% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 709,098 | 0.46% | $1.13M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 535,033 | 0.35% | $850.70K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 438,059 | 0.28% | $613.28K | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 436,778 | 0.28% | $611.49K | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 318,186 | 0.21% | $448.64K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 274,247 | 0.18% | $383.95K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 267,846 | 0.17% | $425.88K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dennis M. Lanfear | President & CEO, Director | 1,567,884 | 1.01% | Jun 2, 2026 |
| Bryan J. McMichael | Chief Financial Officer | 133,736 | 0.09% | Jun 2, 2026 |
| Paul Reider | Chief Commercial Officer | 82,069 | 0.05% | Jan 22, 2025 |
| Ali J. Satvat | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Lee Nisley Newcomer | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Jill O'Donnell-Tormey | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Charles W. Newton | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Rita A. Karachun | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Mats Wahlstrom | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Michael Lee Ryan | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Georgia Erbez | Director | – | – | Jun 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Lee Ryan Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Mats Wahlstrom Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Ali J. Satvat Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Jill O'Donnell-Tormey Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Lee Nisley Newcomer Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Rita A. Karachun Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Charles W. Newton Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Dennis M. Lanfear President & CEO, Director | Jan 23, 2026 | Award | +375,000 | – | – | 1,048,235 |
| Bryan J. McMichael Chief Financial Officer | Jan 22, 2026 | Award | +112,500 | – | – | 133,736 |
| Dennis M. Lanfear President & CEO, Director | Jan 20, 2026 | Tax withholding | −11,839 | $1.55 | $18.35K | 673,235 |
| Bryan J. McMichael Chief Financial Officer | Jan 20, 2026 | Tax withholding | −1,715 | $1.55 | $2.66K | 21,236 |
| Mats Wahlstrom Director | May 23, 2025 | Sale | −99,988 | $0.74 | $73.99K | 0 |
| Dennis M. Lanfear President & CEO, Director | Jan 20, 2025 | Tax withholding | −11,810 | $1.39 | $16.42K | 685,074 |
| Bryan J. McMichael Chief Financial Officer | Jan 20, 2025 | Tax withholding | −1,711 | $1.39 | $2.38K | 22,951 |
| Paul Reider Chief Commercial Officer | Jan 20, 2025 | Tax withholding | −4,858 | $1.39 | $6.75K | 82,069 |
| Bryan J. McMichael Chief Financial Officer | Jan 7, 2025 | Tax withholding | −1,711 | $1.57 | $2.69K | 24,662 |
| Dennis M. Lanfear President & CEO, Director | Jan 4, 2025 | Tax withholding | −11,810 | $1.66 | $19.60K | 696,884 |
| Paul Reider Chief Commercial Officer | Jan 4, 2025 | Tax withholding | −2,277 | $1.66 | $3.78K | 86,927 |
| Paul Reider Chief Commercial Officer | Dec 13, 2024 | Tax withholding | −2,073 | $1.61 | $3.34K | 89,204 |
| Mats Wahlstrom Director | Feb 9, 2024 | Gift | +99,988 | – | – | 99,988 |
| Mats Wahlstrom Director | Feb 9, 2024 | Gift | −99,988 | – | – | 0 |
| Mats Wahlstrom Director | Feb 1, 2024 | Option exercise | +44,991 | $1.67 | $75.13K | 99,988 |
| Mats Wahlstrom Director | Feb 1, 2024 | Option exercise | +14,997 | $1.67 | $25.04K | 54,997 |
| Paul Reider Chief Commercial Officer | Jan 20, 2024 | Tax withholding | −4,854 | $2.44 | $11.84K | 81,277 |
| Dennis M. Lanfear President & CEO, Director | Jan 20, 2024 | Tax withholding | −11,218 | $2.44 | $27.37K | 708,694 |
| Bryan J. McMichael See Remarks | Jan 20, 2024 | Tax withholding | −1,707 | $2.44 | $4.17K | 22,972 |
| Bryan J. McMichael See Remarks | Jan 7, 2024 | Tax withholding | −1,707 | $2.87 | $4.90K | 24,679 |
| Paul Reider Chief Commercial Officer | Jan 4, 2024 | Tax withholding | −2,275 | $2.92 | $6.64K | 86,131 |
| Dennis M. Lanfear President & CEO, Director | Jan 4, 2024 | Tax withholding | −11,781 | $2.92 | $34.40K | 719,912 |
| McDavid Stilwell Chief Financial Officer | Dec 31, 2023 | Tax withholding | −18,440 | $3.33 | $61.41K | 75,305 |
| Paul Reider Chief Commercial Officer | Dec 13, 2023 | Tax withholding | −2,049 | $2.37 | $4.86K | 88,406 |
| Dennis M. Lanfear President & CEO, Director | Nov 22, 2023 | Option exercise | +258,940 | $1.42 | $367.69K | 954,793 |
| Dennis M. Lanfear President & CEO, Director | Nov 22, 2023 | Sale | −223,100 | $2.02 | $450.66K | 731,693 |
| Dennis M. Lanfear President & CEO, Director | Nov 22, 2023 | Option exercise | +41,000 | $1.42 | $58.22K | 695,853 |
| McDavid Stilwell Chief Financial Officer | Apr 1, 2023 | Tax withholding | −3,457 | $6.84 | $23.65K | 102,252 |
| Paul Reider Chief Commercial Officer | Apr 1, 2023 | Tax withholding | −2,451 | $6.84 | $16.76K | 87,053 |
| Vladimir Vexler Chief Scientific Officer | Mar 31, 2023 | Tax withholding | −16,278 | $6.84 | $111.34K | 116,361 |
| Bryan J. McMichael See Remarks | Jan 20, 2023 | Award | +12,500 | – | – | 26,386 |
| McDavid Stilwell Chief Financial Officer | Jan 20, 2023 | Award | +40,000 | – | – | 104,243 |
| Vladimir Vexler Chief Scientific Officer | Jan 20, 2023 | Award | +40,000 | – | – | 131,323 |
| Dennis M. Lanfear President & CEO, Director | Jan 20, 2023 | Award | +86,250 | – | – | 654,853 |
| Vladimir Vexler Chief Scientific Officer | Jan 11, 2023 | Tax withholding | −3,602 | $10.26 | $36.96K | 91,323 |
| Vladimir Vexler Chief Scientific Officer | Jan 10, 2023 | Tax withholding | −3,602 | $9.85 | $35.48K | 94,925 |
| Bryan J. McMichael See Remarks | Jan 7, 2023 | Tax withholding | −1,699 | $9.58 | $16.28K | 13,886 |
| Vladimir Vexler Chief Scientific Officer | Jan 4, 2023 | Tax withholding | −5,437 | $9.87 | $53.66K | 98,527 |
| McDavid Stilwell Chief Financial Officer | Jan 4, 2023 | Tax withholding | −5,437 | $9.87 | $53.66K | 64,243 |
| Dennis M. Lanfear President & CEO, Director | Jan 4, 2023 | Tax withholding | −10,905 | $9.87 | $107.63K | 568,603 |
| Dennis M. Lanfear President & CEO, Director | Dec 30, 2022 | Gift | −4,000 | – | – | 432,684 |
| McDavid Stilwell Chief Financial Officer | Apr 1, 2022 | Tax withholding | −3,458 | $12.85 | $44.44K | 69,680 |
| Vladimir Vexler Chief Scientific Officer | Apr 1, 2022 | Tax withholding | −3,458 | $12.85 | $44.44K | 103,963 |
| Mats Wahlstrom Director | Feb 28, 2022 | Award | +29,994 | $2.08 | $62.39K | 40,000 |
| Mats Wahlstrom Director | Feb 25, 2022 | Award | +10,006 | $11.64 | $116.47K | 10,006 |
| Vladimir Vexler Chief Scientific Officer | Jan 11, 2022 | Tax withholding | −3,583 | $14.36 | $51.45K | 107,421 |
| Vladimir Vexler Chief Scientific Officer | Jan 10, 2022 | Tax withholding | −4,150 | $14.30 | $59.35K | 111,004 |
| Dennis M. Lanfear President & CEO, Director | Jan 4, 2022 | Award | +86,250 | – | – | 579,508 |
| Vladimir Vexler Chief Scientific Officer | Jan 4, 2022 | Award | +40,000 | – | – | 115,154 |
| McDavid Stilwell Chief Financial Officer | Jan 4, 2022 | Award | +40,000 | – | – | 73,138 |
| Dennis M. Lanfear President & CEO, Director | Nov 17, 2021 | Gift | −10,000 | – | – | 436,684 |
| McDavid Stilwell Chief Financial Officer | Oct 15, 2021 | Sale | −3,507 | $16.80 | $58.92K | 31,611 |
| James Healy Director | Sep 29, 2021 | Sale | −286,076 | $16.12 | $4.61M | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Dennis M. Lanfear Officer | Nov 22, 2023 | 223,100 | $449.78K | Nov 22, 2023 | STOCK OPTION EXERCISE |